Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06565923

Study on the Staging and Prognosis Model of Bladder Cancer

Firstly, we retrospectively gathered the patient information who compliant with the criteria from 2012 to 2023, encompassing basic information, clinical information, along with MRI images, blood/urine samples, and tissue samples, for conducting relevant analyses of radiomics. Subsequently, based on artificial intelligence technology, deep learning and machine learning models were established on the basis of MRI radiomics and pathological histomics. Ultimately, the following research aims were accomplished: 1. Primary research objective: To explore the role of artificial intelligence and multimodal omics features in the staging and prognosis monitoring of bladder cancer. 2. Secondary objective: To explore the correlations among radiomics, case histomics, and test omics.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Bladder Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Neoplasms Neoplasms by Site Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital with Nanjing Medical University

Nanjing, Jiangsu, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Patients with bladder cancer in preoperative examination; 2. Gender is not limited; 3. Age≥ 18 years old; 4. Be able to provide MRI images, pathological data and laboratory examination data before the operation; 5. Agree to provide basic personal clinical information and pathological and imaging data for scientific research use, and sign the informed consent form; 6. Agree to provide monitoring results during follow-up recurrence monitoring;

Exclusion criteria

  • 1. Incomplete clinicopathological data; 2. Combined with upper tract urothelial carcinoma or previously diagnosed upper tract urothelial carcinoma; 3. Is participating in the rest of the clinical studies; Unable to cooperate with the relevant examinations of this project, and do not agree to sign the informed consent form.

Treatment and study plan

Primary outcomes

  1. Overall survival (OS)

    Time frame: 2013-

    Overall survival (OS) is defined as the duration from surgery to death or the date of the last follow-up.

  2. Progression-free survival (PFS)

    Time frame: 2013-

    Progression-free survival (PFS) refers to the time from surgery until disease progression, the date of the last follow-up, or death from causes other than disease recurrence

  3. Recurrence-Free Survival (RFS)

    Time frame: 2013-

    Recurrence-Free Survival (RFS)

Secondary outcomes

  1. Tumor Infiltration Status

    Time frame: 2013-

    Tumor Infiltration Status

  2. Lymph node metastasis status

    Time frame: 2013-

    Lymph node metastasis status

Other outcomes

  1. Neoadjuvant and Adjuvant Treatment Effects

    Time frame: 2013-

    Neoadjuvant and Adjuvant Treatment Effects

Sponsors and collaborators

Lead sponsor

The First Affiliated Hospital with Nanjing Medical University

Other

Collaborators

  • Huai an First People Hospital
  • Jiangsu Province Hospital of Traditional Chinese Medicine
  • Suzhou Municipal Hospital
  • The First Affiliated Hospital of Zhengzhou University
  • The second affiliated hospital of Xuzhou medical university
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Yixing People's Hospital

Registry information

Official study title

Study on the Staging and Prognosis Model of Bladder Cancer Based on Artificial Intelligence and Multimodal Omics Features

Acronym: 2024-SR-386

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Aug 22, 2024
Registry last updated
Aug 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.